CVSI CV Sciences Inc

CV Sciences, Inc. Announces Distribution Expansion Into Food, Drug and Mass Channels

CV Sciences, Inc. Announces Distribution Expansion Into Food, Drug and Mass Channels

LAS VEGAS, April 10, 2019 (GLOBE NEWSWIRE) -- (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp CBD products, is pleased to announce further expansion of its industry-dominating brand, As of March 31, 2019, PlusCBD Oil™ branded products are available in 3,308 retail stores, up 48% from 2,238 retail stores as of December 31, 2018.

The expansion includes broadening distribution of its best-selling topical, PlusCBD Oil™ Extra Strength Balm, into the Food, Drug and Mass (FDM) channel, including programs with leading national retailers.

“The passage of the 2018 Farm Bill has accelerated our business development activities and expanded our distribution to new food, drug, mass merchandise retailers,” said Joseph Dowling, Chief Executive Officer. “We are at an important stage in the development of the hemp-based CBD market, and the company is well-positioned to capitalize on both growing consumer demand and the benefit of enhanced regulation that supports and ensures the safest and highest quality hemp-based CBD products for consumers.”

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing synthetic CBD. The Company’s PlusCBD Oil™ is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Investor Contact:

ICR

Scott Van Winkle

617-956-6736

Media Contact:

ICR

Cory Ziskind

646-277-1232

EN
10/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CV Sciences Inc

 PRESS RELEASE

CV Sciences, Inc. Reports First Quarter 2022 Financial Results

CV Sciences, Inc. Reports First Quarter 2022 Financial Results SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Financial and Operating Highlights Revenue of $4.4 million for first quarter of 2022, compared to $4.8 million for the first quarter of 2021;Gross margin of 26.0% for first quarter of 2022, compared to 32.4% for t...

 PRESS RELEASE

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2...

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) --  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2022, before the stock market opens on Monday, May 16, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day. The webcast of the conference call will be ...

 PRESS RELEASE

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2021. Fiscal 2021 and Recent Financial and Operating Highlights Revenue of $20.0 million for fiscal year 2021, compared to $24.4 million for 2020;Gross margin of 43.0% for fiscal year 2021, compared to 45.1% for 2020;Total cash balance of $1.4 million a...

 PRESS RELEASE

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Result...

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022 SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) --  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2021, after the stock market closes on Thursday, March 31, 2022. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The ...

 PRESS RELEASE

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line o...

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch